Read the full publication here.
“Optimizing pediatric melatonin therapy through semi-solid extrusion of tailored dosage forms” is now out (open access)!
This is the third article in our collaboration with St. Jude Children's Research Hospital, following our work on pediatric corticosteroids and ondansetron.
Together, these studies build a growing body of peer-reviewed evidence for automated 3D-printed compounding in US health system pharmacies.
Melatonin is widely used for sleep problems in children, but commercial strengths rarely allow the fine dose adjustments that infants, smaller children, and kids with neurodevelopmental conditions need. In this study, we compounded melatonin on the CurifyLabs Pharma Printer in three child-friendly forms: chewable CuraBlend gel tablets, anhydrous troches, and orodispersible films, covering doses from 0.8 to 12.5 mg.
Key results:
✅ All printed tablets and films met pharmacopoeia requirements for mass and content uniformity
✅ Stable assay results over three months
✅ Orodispersible films released nearly all of their melatonin within 3 minutes
✅ The validated process was transferred to the hospital pharmacy at St. Jude and reproduced there with the same quality controls
A heartfelt thank you to our St. Jude co-authors and the Department of Pharmacy and Pharmaceutical Sciences: Brooke Bernhardt, Cindy Brasher, Sophie Tilley. Your clinical insight, rigor, and dedication to patients made this work possible. Thank you also to our CurifyLabs Pharmaceutical Development team and Åbo Akademi University colleagues.
Today, CurifyLabs technology is used by compounding pharmacies in 30 US states and in clinical practice at compounding pharmacies and hospitals across Europe. Research like this keeps expanding what pharmacists can prepare for their patients, with the precision and traceability that personalized medicine demands. More to come!
Read the full publication here.